TECHNICAL SPECIFICATIONS

1.MECHANISM OF ACTION

This peptide functions as a specific antigenic determinant for CD8+ cytotoxic T lymphocytes (CTLs). Within melanoma cells, the intracellular proteasome processes the full-length gp100 protein, generating this 9-mer fragment, which is then transported into the endoplasmic reticulum, loaded onto HLA-A0201 molecules, and presented on the cell surface. As an exogenous synthetic peptide, it can be directly loaded onto the HLA-A0201 molecules of antigen-presenting cells (APCs) in vitro. The resulting peptide-MHC complex is specifically recognized by T-cell receptors (TCRs) on gp100 (639-647)-specific CTLs.

2.PRODUCT INDICATIONS

Melanoma Antigen-Specific T-Cell Studies: Analyzing the frequency, functional avidity, and memory phenotype of gp100 (639-647)-reactive CD8+ T cells in the peripheral blood or tumor microenvironment of melanoma patients.

In VitroCTL Generation & Expansion: Stimulating and expanding antigen-specific human CTL lines or clones from HLA-A*0201-positive donor PBMCs for use in functional cytotoxicity assays and adoptive cell therapy research.

Immune Monitoring & Validation: Serving as the target antigen in standardized immune monitoring assays, including interferon-gamma ELISPOT, intracellular cytokine staining (ICS) by flow cytometry, and HLA-A*0201 tetramer staining for tracking antigen-specific T-cell responses in clinical trial samples.

Cancer Vaccine Development: Evaluating the immunogenicity and protective efficacy of this epitope in preclinical peptide-based, dendritic cell-based, or nucleic acid-based vaccine models for melanoma.

 

3.CLINICAL EFFICACY OF PRODUCT

Immunogenic Validation: This epitope is one of several defined immunogenic peptides from gp100 that have been shown to consistently elicit specific CD8+ T-cell responses in HLA-A*0201+ melanoma patients and healthy donors, confirming its relevance as a tumor-associated antigen.

Clinical Trial History: The gp100 (639-647) epitope, often alongside other gp100 peptides, has been incorporated into numerous clinical trials of peptide-based vaccines for metastatic melanoma, frequently administered with immune adjuvants (e.g., Montanide ISA-51) or cytokines (e.g., IL-2, GM-CSF).

Therapeutic Modality Context: While standalone peptide vaccines have shown limited objective response rates, this epitope remains a critical target for more potent adoptive T-cell therapy (ACT). Clinical trials utilizing T-cells engineered with TCRs recognizing gp100 epitopes, including the 639-647 epitope, have demonstrated measurable tumor regression in a subset of patients with metastatic melanoma.

  

4.DELIVERY & SHIPPING


We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods 
Main Method: International Air Freight


We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.